1. In vitro antioxidant properties of the iron chelator pyridoxal isonicotinoyl hydrazone and some of its analogs
- Author
-
E.M. Wang, Herbert M. Schulman, Prem Ponka, and Marcelo Hermes-Lima
- Subjects
Liposome ,Antioxidant ,010405 organic chemistry ,Physiology ,medicine.medical_treatment ,Radical ,Biochemistry (medical) ,Clinical Biochemistry ,Cell Biology ,010402 general chemistry ,medicine.disease_cause ,01 natural sciences ,Biochemistry ,In vitro ,0104 chemical sciences ,Ferrous ,Lipid peroxidation ,chemistry.chemical_compound ,Salicylaldehyde ,chemistry ,medicine ,Oxidative stress - Abstract
Since there are several problems with desferrioxamine (DFO) therapy, pyridoxal isonicotinoyl hydrazone (PIH) has been studied for more than 10 years as a promising new candidate for iron chelation therapy in iron-overload diseases. Iron chelation could also be helpful for experimental treatment of several other pathologies including rheumatoid arthritis and heart ischemia/reperfusion, due to the generation of oxyradicals and lipid peroxidation mediated by delocalized iron. We demonstrate here that sub-millimolar levels of PIH can inhibit the Fe(III)-EDTA/ascorbate-mediated formation of hydroxyl-like radicals as tested by the release of ethylene from 2-keto-4-methylthiobutyric acid (KMB assay) and the formation of malonaldehyde from 2-deoxyribose damage. PIH could also decrease the rates of Fe(III)-EDTA-mediated oxidation of ascorbate and block the peroxidation of liposomes of rat brain phospholipids induced by ferrous iron-EDTA. In all cases the in vitro antioxidant effectiveness of PIH was comparable to its analogs-including salicylaldehyde isonicotinoyl hydrazone-and to DFO. We conclude that PIH and its analogs are effective new candidates against iron-mediated oxidative stress for use in experimental medicine.
- Published
- 2016